Parker Labs Leads Investment in Solstice Pharmaceuticals’ Innovative Ultrasound Contrast Agent
ENSCHEDE, Netherlands & FAIRFIELD, N.J., July 7, 2021 /PRNewswire/ — Solstice Pharmaceuticals has successfully completed its latest round of funding to further the clinical development of its innovative ultrasound contrast agent (UCA). The first-of-its-kind contrast agent uses unique…
Comments Off on Parker Labs Leads Investment in Solstice Pharmaceuticals’ Innovative Ultrasound Contrast Agent